Sodium‐glucose cotransporter‐2 inhibitors and the risk of lung cancer among patients with type 2 diabetes

Documenti analoghi

• Sodium–glucose cotransporter 2 inhibitor increases risk of urinary tract infection: Evidence from mendelian randomization and meta‐analysis
  di: Jie Ren, et al.
  Pubblicazione: (2025)
• Cardiovascular benefits of early sodium‐glucose cotransporter 2 inhibitor use for diabetics with acute myocardial infarction: A nationwide cohort study
  di: Sheng‐Fan Wang, et al.
  Pubblicazione: (2025)
• Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users
  di: Haoxin Le, et al.
  Pubblicazione: (2026)
• Prevalence of potentially inappropriate medications among newly treated patients with type 2 diabetes in UK primary care
  di: Maria Luisa Faquetti, et al.
  Pubblicazione: (2024)
• Pharmacokinetics and pharmacodynamics of empagliflozin in paediatric patients aged 10–17 years with type 2 diabetes mellitus
  di: Juliane Rascher, et al.
  Pubblicazione: (2025)